46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Nlrp3 inflammasome regulates acute graft-versus-host disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Conditioning therapies before transplantation induce the release of uric acid, which triggers the NLRP3 inflammasome and IL-1β production contributing to graft-versus-host disease.

          Abstract

          The success of allogeneic hematopoietic cell transplantation is limited by acute graft-versus-host disease (GvHD), a severe complication accompanied by high mortality rates. Yet, the molecular mechanisms initiating this disease remain poorly defined. In this study, we show that, after conditioning therapy, intestinal commensal bacteria and the damage-associated molecular pattern uric acid contribute to Nlrp3 inflammasome–mediated IL-1β production and that gastrointestinal decontamination and uric acid depletion reduced GvHD severity. Early blockade of IL-1β or genetic deficiency of the IL-1 receptor in dendritic cells (DCs) and T cells improved survival. The Nlrp3 inflammasome components Nlrp3 and Asc, which are required for pro–IL-1β cleavage, were critical for the full manifestation of GvHD. In transplanted mice, IL-1β originated from multiple intestinal cell compartments and exerted its effects on DCs and T cells, the latter being preferentially skewed toward Th17. Compatible with these mouse data, increased levels of active caspase-1 and IL-1β were found in circulating leukocytes and intestinal GvHD lesions of patients. Thus, the identification of a crucial role for the Nlrp3 inflammasome sheds new light on the pathogenesis of GvHD and opens a potential new avenue for the targeted therapy of this severe complication.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Graft-versus-host disease.

          Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk haematological malignant disorders and other life-threatening haematological and genetic diseases. The main complication of HCT is graft-versus-host disease (GVHD), an immunological disorder that affects many organ systems, including the gastrointestinal tract, liver, skin, and lungs. The number of patients with this complication continues to grow, and many return home from transplant centres after HCT requiring continued treatment with immunosuppressive drugs that increases their risks for serious infections and other complications. In this Seminar, we review our understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease. We also summarise supportive-care measures that are essential for management of this medically fragile population.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The inflammasomes: guardians of the body.

            The innate immune system relies on its capacity to rapidly detect invading pathogenic microbes as foreign and to eliminate them. The discovery of Toll-like receptors (TLRs) provided a class of membrane receptors that sense extracellular microbes and trigger antipathogen signaling cascades. More recently, intracellular microbial sensors have been identified, including NOD-like receptors (NLRs). Some of the NLRs also sense nonmicrobial danger signals and form large cytoplasmic complexes called inflammasomes that link the sensing of microbial products and metabolic stress to the proteolytic activation of the proinflammatory cytokines IL-1beta and IL-18. The NALP3 inflammasome has been associated with several autoinflammatory conditions including gout. Likewise, the NALP3 inflammasome is a crucial element in the adjuvant effect of aluminum and can direct a humoral adaptive immune response. In this review, we discuss the role of NLRs, and in particular the inflammasomes, in the recognition of microbial and danger components and the role they play in health and disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

              Alum (aluminum hydroxide) is the most widely used adjuvant in human vaccines, but the mechanism of its adjuvanticity remains unknown. In vitro studies showed no stimulatory effects on dendritic cells (DCs). In the absence of adjuvant, Ag was taken up by lymph node (LN)–resident DCs that acquired soluble Ag via afferent lymphatics, whereas after injection of alum, Ag was taken up, processed, and presented by inflammatory monocytes that migrated from the peritoneum, thus becoming inflammatory DCs that induced a persistent Th2 response. The enhancing effects of alum on both cellular and humoral immunity were completely abolished when CD11c+ monocytes and DCs were conditionally depleted during immunization. Mechanistically, DC-driven responses were abolished in MyD88-deficient mice and after uricase treatment, implying the induction of uric acid. These findings suggest that alum adjuvant is immunogenic by exploiting “nature's adjuvant,” the inflammatory DC through induction of the endogenous danger signal uric acid.
                Bookmark

                Author and article information

                Journal
                J Exp Med
                J. Exp. Med
                jem
                The Journal of Experimental Medicine
                The Rockefeller University Press
                0022-1007
                1540-9538
                23 September 2013
                : 210
                : 10
                : 1899-1910
                Affiliations
                [1 ]Department of Dermatology, University Hospital, CH-8091 Zürich, Switzerland
                [2 ]Department of Hematology and Oncology , [3 ]Department of Pneumology , [4 ]Allergy Research Group, Department of Dermatology , and [5 ]Department of Pathology, University Medical Center Freiburg ; [6 ]Faculty of Biology ; [7 ]Spemann Graduate School of Biology and Medicine (SGBM) , and [8 ]Centre for Biological Signaling Studies BIOSS, Albert-Ludwigs-University, 79085 Freiburg, Germany
                [9 ]III. Medizinische Klinik, Klinikum Rechts der Isar and [10 ]Institut für Klinische Chemie und Pathobiochemie, Klinikum Rechts der Isar, Technische Universität München, 80333 München, Germany
                [11 ]Biochemistry Institute, University of Lausanne, CH-1066 Epalinges, Switzerland
                [12 ]Department of Hematology and Oncology, University Hospital Regensburg, 93052 Regensburg, Germany
                Author notes

                D. Jankovic, J. Ganesan, and M. Bscheider contributed equally to this paper.

                H. Poeck, E. Contassot, and R. Zeiser contributed equally to this paper.

                J. Ganesan’s present address is ProQinase GmbH, Freiburg, Germany.

                A. Manoharan’s present address is the Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.

                Article
                20130084
                10.1084/jem.20130084
                3782050
                23980097
                26c87d25-d4b8-4250-83b8-61733c0ea68e
                © 2013 Jankovic et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

                History
                : 11 January 2013
                : 31 July 2013
                Categories
                Brief Definitive Report

                Medicine
                Medicine

                Comments

                Comment on this article